Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis

microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic...

Full description

Saved in:
Bibliographic Details
Published in:Hepatobiliary & pancreatic diseases international 2019-08, Vol.18 (4), p.321-331
Main Authors: Chen, Jian-An, Yu, Yan, Xue, Chen, Chen, Xiao-Long, Cui, Guang-Ying, Li, Juan, Li, Kong-Fei, Ren, Zhi-Gang, Sun, Ran-Ran
Format: Article
Language:English
Subjects:
Aged
Biomarkers, Tumor - genetics
Databases, Genetic
Down-Regulation
Female
Gene Expression Regulation, Neoplastic
GEO database
Humans
Male
microRNA-139
microRNAs
MicroRNAs - genetics
Middle Aged
Neoplasms - genetics
Neoplasms - mortality
Neoplasms - pathology
Neoplasms - therapy
Prognosis
Risk Factors
TCGA dataset
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic values of miR-139 in solid tumors. PubMed, Web of Science and Embase databases were searched and publications from January 2011 to August 2017 were included. We used Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database to further validate this meta-analysis. Eight individual studies from seven articles were included. Pooled analyses showed that low miR-139 expression was related to worse overall survival (OS) [hazard ratio (HR) = 2.27; 95% confidence intervals (CI): 1.74–2.95; P 
ISSN:1499-3872
DOI:10.1016/j.hbpd.2018.09.016